Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2007

View Archived Issues

Recombinant T-cell receptor ligand to be examined in phase I trial for multiple sclerosis

Fovea licenses RdCVF therapy for retinal degeneration

Nicholas Piramal and Lilly sign new drug development agreement

Intercell completes acquisition of Pelias

European grant for VASOPLUS consortium's proangiogenesis program

Third interim analysis due in pivotal breast cancer study of tesmilifene

Cleveland BioLabs enters research partnership with Roswell Park Cancer Institute

Novo Nordisk focuses R&D on therapeutic proteins

RX-100 shown to protect against lethal whole-body radiation

U.S. orphan drug designation for LX-211 in uveitis

Dermylex available in Canada for psoriasis

CAT-192 ineffective in early stage systemic sclerosis

BMS-201038 effective in familial hypercholesterolemia

Novel agents for treating endocrine-related disorders disclosed in recent patents

New treatment options for inflammatory disorders disclosed in recent patent literature

Recent Actelion patent discloses new agents for transplant rejection and graft-versus-host disease

Omega-3 polyunsaturated fatty acids may regulate the nociceptive TRPV1 channel

First European approval for Wellbutrin XR

Neupro now approved in Europe for all stages of Parkinson's disease

FDA approves Lialda in ulcerative colitis

New European approval for Keppra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...